Targeting Histone Deacetylases in Diseases: Where Are We?
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
SIGNIFICANCE: Epigenetic inactivation of pivotal genes involved in cell growth is a hallmark of human pathologies, in particular cancer. Histone acetylation balance obtained through opposing actions of histone deacetylases (HDACs) and histone acetyltransferases is one epigenetic mechanism controlling gene expression and is, thus, associated with disease etiology and progression. Interfering pharmacologically with HDAC activity can correct abnormalities in cell proliferation, migration, vascularization, and death. RECENT ADVANCES: Histone deacetylase inhibitors (HDACi) represent a new class of cytostatic agents that interfere with the function of HDACs and are able to increase gene expression by indirectly inducing histone acetylation. Several HDACi, alone or in combination with DNA-demethylating agents, chemopreventive, or classical chemotherapeutic drugs, are currently being used in clinical trials for solid and hematological malignancies, and are, thus, promising candidates for cancer therapy. CRITICAL ISSUES: (i) Non-specific (off-target) HDACi effects due to activities unassociated with HDAC inhibition. (ii) Advantages/disadvantages of non-selective or isoform-directed HDACi. (iii) Limited number of response-predictive biomarkers. (iv) Toxicity leading to dysfunction of critical biological processes. FUTURE DIRECTIONS: Selective HDACi could achieve enhanced clinical utility by reducing or eliminating the serious side effects associated with current first-generation non-selective HDACi. Isoform-selective and pan-HDACi candidates might benefit from the identification of biomarkers, enabling better patient stratification and prediction of response to treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
The complex language of chromatin regulation during transcription
Berger, S. L. (2007) · Nature · doi:10.1038/nature05915 · Cited by 2,768
HDAC6 is a microtubule-associated deacetylase
Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X.-F., & Yao, T.-P. (2002) · Nature · doi:10.1038/417455a · Cited by 2,403 · cited 1×
“HDAC6 and the enzyme functions as a tubulin deacetylase (98, 144, 257).”
BackgroundAcetylation and deacetylation of non-histone proteins
Glozak, M. A., Sengupta, N., Zhang, X., & Seto, E. (2005) · Gene · doi:10.1016/j.gene.2005.09.010 · Cited by 1,584 · cited 1×
“HDACs catalyse the removal of acetyl groups from the amino-terminal lysine residues of histone and non-histone proteins, such as transcription factors (TFs), hormone receptors, signaling proteins, chaperones, and DNA damage response proteins (10, 47, 68, 78).”
BackgroundInhibition of Histone Deacetylase Activity by Butyrate
Davie, J. R. (2003) · The Journal of Nutrition · doi:10.1093/jn/133.7.2485s · Cited by 1,515
Protein degradation by the ubiquitin-proteasome pathway in normal and disease states
Lecker, S. H., Goldberg, A. L., & Mitch, W. E. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006010083 · Cited by 1,234
Zhang, Y., Ng, H.-H., Erdjument-Bromage, H., Tempst, P., Bird, A., & Reinberg, D. (1999) · Genes & Development · doi:10.1101/gad.13.15.1924 · Cited by 1,103 · cited 1×
“Both Sin3 and NuRD complexes consist of a core containing HDAC1 and 2, Rb-associated protein 48 and RbAp46 (123, 258).”
BackgroundHDAC family: What are the cancer relevant targets?
Witt, O., Deubzer, H. E., Milde, T., & Oehme, I. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.08.016 · Cited by 1,069 · cited 1×
“Increased HDAC6 expression has been observed in more advanced—compared with early-stage cancers (239).”
BackgroundAdiponectin and AdipoR1 Regulate PGC-1α and Mitochondria by Ca2+ and AMPK/SIRT1
Iwabu, M., Yamauchi, T., Okada-Iwabu, M., Sato, K., Nakagawa, T., Funata, M., Yamaguchi, M., Namiki, S., Nakayama, R., Tabata, M., et al. (2010) · Nature · doi:10.1038/nature08991 · Cited by 971
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914 · cited 1×
“The pan-inhibitor Vorinostat inhibits (177) HDAC1 and 3 with IC50 = 10 and 20 nM, respectively.”
Mattagajasingh, I., Kim, C.-S., Naqvi, A., Yamamori, T., Hoffman, T. A., Jung, S.-B., DeRicco, J., Kasuno, K., & Irani, K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704329104 · Cited by 881
Acetylation Is Indispensable for p53 Activation
Tang, Y., Zhao, W., Chen, Y., Zhao, Y., & Gu, W. (2008) · Cell · doi:10.1016/j.cell.2008.03.025 · Cited by 838
Gao, L., Cueto, M. A., Asselbergs, F., & Atadja, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111871200 · Cited by 744 · cited 4×
“HDAC11, containing a catalytic domain at the N-terminus, is similar to HDAC3 and 8, suggesting that it might be more closely related to class I than to class II HDACs (71).”
BackgroundInfluentialHDAC-6 interacts with and deacetylates tubulin and microtubules in vivo
Zhang, Y., Li, N., Caron, C., Matthias, G., Hess, D., Khochbin, S., & Matthias, P. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg115 · Cited by 740 · cited 1×
“HDAC6 and the enzyme functions as a tubulin deacetylase (98, 144, 257).”
BackgroundIn vivo destabilization of dynamic microtubules by HDAC6‐mediated deacetylation
Matsuyama, A., Shimazu, T., Sumida, Y., Saito, A., Yoshimatsu, Y., Seigneurin‐Berny, D., Osada, H., Komatsu, Y., Nishino, N., Khochbin, S., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf682 · Cited by 720 · cited 1×
“HDAC6 and the enzyme functions as a tubulin deacetylase (98, 144, 257).”
BackgroundTelomere shortening and apoptosis in telomerase-inhibited human tumor cells
Zhang, X., Mar, V., Zhou, W., Harrington, L., & Robinson, M. O. (1999) · Genes & Development · doi:10.1101/gad.13.18.2388 · Cited by 698
Chromatin deacetylation by an ATP-dependent nucleosome remodelling complex
Tong, J. K., Hassig, C. A., Schnitzler, G. R., Kingston, R. E., & Schreiber, S. L. (1998) · Nature · doi:10.1038/27699 · Cited by 692
HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics
Gallinari, P., Marco, S. D., Jones, P., Pallaoro, M., & Steinkühler, C. (2007) · Cell Research · doi:10.1038/sj.cr.7310149 · Cited by 678 · cited 1×
“HDACs catalyse the removal of acetyl groups from the amino-terminal lysine residues of histone and non-histone proteins, such as transcription factors (TFs), hormone receptors, signaling proteins, chaperones, and DNA damage response proteins (10, 47, 68, 78).”
BackgroundClass II histone deacetylases: versatile regulators
Verdin, E., Dequiedt, F., & Kasler, H. G. (2003) · Trends in Genetics · doi:10.1016/s0168-9525(03)00073-8 · Cited by 664 · cited 1×
“Class II HDACs (229) are present in both the cytoplasm and nucleus, and they shuttle between these compartments (113, 147, 234).”
BackgroundVannini, A., Volpari, C., Filocamo, G., Casavola, E. C., Brunetti, M., Renzoni, D., Chakravarty, P., Paolini, C., De Francesco, R., Gallinari, P., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404603101 · Cited by 638 · cited 3×
“HDAC8 (69, 224, 225) consists largely of the catalytic domain with a nuclear localization signal.”
BackgroundThe SMRT and N-CoR Corepressors Are Activating Cofactors for Histone Deacetylase 3
Guenther, M. G., Barak, O., & Lazar, M. A. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.18.6091-6101.2001 · Cited by 611
Histone Deacetylases and SAP18, a Novel Polypeptide, Are Components of a Human Sin3 Complex
Zhang, Y., Iratni, R., Erdjument-Bromage, H., Tempst, P., & Reinberg, D. (1997) · Cell · doi:10.1016/s0092-8674(00)80216-0 · Cited by 578 · cited 2×
“Many HDACs exist as components of multi-protein complexes, such as the transcriptional co-repressors mSin3, NCoR, and SMRT (97, 215, 217, 245, 256, 259).”
BackgroundTargeted Cancer Therapy: Giving Histone Deacetylase Inhibitors All They Need To Succeed
Gryder, B. E., Sodji, Q. H., & Oyelere, A. K. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.3 · Cited by 404
Sirtuins: The ‘ magnificent seven ’, function, metabolism and longevity
Dali‐Youcef, N., Lagouge, M., Froelich, S., Koehl, C., Schoonjans, K., & Auwerx, J. (2007) · Annals of Medicine · doi:10.1080/07853890701408194 · Cited by 402 · cited 1×
“Sirtuins, related to Sir2 in yeast (42), have also been categorized as class III HDACs (165) (Fig.”
BackgroundHistone deacetylase 8 in neuroblastoma tumorigenesis
Oehme, I., Deubzer, H. E., Wegener, D., Pickert, D., Linke, J.-P., Hero, B., Kopp-Schneider, A., Westermann, F., Ulrich, S. M., von Deimling, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0684 · Cited by 398 · cited 1×
“Unlike other class I members, HDAC8 expression appears to be cancer-type specific, as to date it has been found altered in childhood neuroblastoma (166, 167) and pancreatic ductal adenocarcinoma (48).”
BackgroundIsoform-selective histone deacetylase inhibitors
Bieliauskas, A. V., & Pflum, M. K. H. (2008) · Chemical Society Reviews · doi:10.1039/b703830p · Cited by 350 · cited 1×
“While the capping group has been successfully modified for the design of several class-selective inhibitors (17), a combination of modifications at all three regions likely enhances their selective function.”
BackgroundThe functional interactome landscape of the human histone deacetylase family
Joshi, P., Greco, T. M., Guise, A. J., Luo, Y., Yu, F., Nesvizhskii, A. I., & Cristea, I. M. (2013) · Molecular Systems Biology · doi:10.1038/msb.2013.26 · Cited by 289
Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus
Christensen, D. P., Dahllöf, M., Lundh, M., Rasmussen, D. N., Nielsen, M. D., Billestrup, N., Grunnet, L. G., & Mandrup-Poulsen, T. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00021 · Cited by 261
Molecular Cloning and Characterization of a Novel Histone Deacetylase HDAC10
Guardiola, A. R., & Yao, T.-P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109861200 · Cited by 253 · cited 1×
“HDAC10 might function as a recruiter rather than as a deacetylase (85), interacting with HDAC1, 2, 3, 4, 5, and 7, but not with HDAC6, with some contradictions present in literature.”
BackgroundUV Irradiation Triggers Ubiquitin-Dependent Degradation of p21WAF1 to Promote DNA Repair
Bendjennat, M., Boulaire, J., Jascur, T., Brickner, H., Barbier, V., Sarasin, A., Fotedar, A., & Fotedar, R. (2003) · Cell · doi:10.1016/j.cell.2003.08.001 · Cited by 248 · cited 1×
“Overexpression of p21 also correlates with the start of biochemical processes, leading to DNA repair (12, 100).”
BackgroundJin, Y.-H., Jeon, E.-J., Li, Q.-L., Lee, Y. H., Choi, J.-K., Kim, W.-J., Lee, K.-Y., & Bae, S.-C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313120200 · Cited by 211
Isolation and Characterization of Mammalian HDAC10, a Novel Histone Deacetylase
Kao, H.-Y., Lee, C.-H., Komarov, A., Han, C. C., & Evans, R. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108931200 · Cited by 193 · cited 7×
“HDAC10 (112) is closely related (37% overall similarity) to HDAC6.”
BackgroundInfluentialJung, M., Brosch, G., Kölle, D., Scherf, H., Gerhäuser, C., & Loidl, P. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm991091h · Cited by 176 · cited 4×
“HDACi derive from natural or synthetic sources and can be classified into five main groups (16): (i) Hydroxamates, including trichostatin A (TSA), suberoylanilide hydroxamic acid (also called Vorinostat), LAQ824, LBH589 (Panabinostat), or PXD101 (Belinostat), M344, CR2408, abexinostat hydrochloride (PCI-24781) (ii) al…”
BackgroundInfluentialCloning and characterization of human histone deacetylase 8
Van den Wyngaert, I., de Vries, W., Kremer, A., Neefs, J.-M., Verhasselt, P., Luyten, W. H. M. L., & Kass, S. U. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01813-5 · Cited by 143
DNA damage in stem cells activates p21, inhibits p53, and induces symmetric self-renewing divisions.
Insinga, A., Cicalese, A., Faretta, M., Gallo, B., Albano, L., Ronzoni, S., Furia, L., Viale, A., & Pelicci, P. G. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213394110 · Cited by 140 · cited 1×
“Overexpression of p21 also correlates with the start of biochemical processes, leading to DNA repair (12, 100).”
BackgroundBuggy, J. J., Cao, Z. A., Bass, K. E., Verner, E., Balasubramanian, S., Liu, L., Schultz, B. E., Young, P. R., & Dalrymple, S. A. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0442 · Cited by 127
HDAC11 is a novel drug target in carcinomas
Deubzer, H. E., Schier, M. C., Oehme, I., Lodrini, M., Haendler, B., Sommer, A., & Witt, O. (2013) · International Journal of Cancer · doi:10.1002/ijc.27876 · Cited by 112
Toffolo, E., Rusconi, F., Paganini, L., Tortorici, M., Pilotto, S., Heise, C., Verpelli, C., Tedeschi, G., Maffioli, E., Sala, C., et al. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12457 · Cited by 106 · cited 2×
“Many HDACs exist as components of multi-protein complexes, such as the transcriptional co-repressors mSin3, NCoR, and SMRT (97, 215, 217, 245, 256, 259).”
Background
Cited by
Zhong, Q., Xiao, X., Qiu, Y., Xu, Z., Chen, C., Chong, B., Zhao, X., Hai, S., Li, S., An, Z., et al. (2023) · MedComm · doi:10.1002/mco2.261 · Cited by 442
Milazzo, G., Mercatelli, D., Di Muzio, G., Triboli, L., De Rosa, P., Perini, G., & Giorgi, F. M. (2020) · Genes · doi:10.3390/genes11050556 · Cited by 423
Zinc binding groups for histone deacetylase inhibitors
Zhang, L., Zhang, J., Jiang, Q., Zhang, L., & Song, W. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2017.1417274 · Cited by 240
Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology
Shah, R. R. (2019) · Drug Safety · doi:10.1007/s40264-018-0773-9 · Cited by 197
Strategies To Design Selective Histone Deacetylase Inhibitors
Melesina, J., Simoben, C. V., Praetorius, L., Bülbül, E. F., Robaa, D., & Sippl, W. (2021) · ChemMedChem · doi:10.1002/cmdc.202000934 · Cited by 118
Metadata
- Authors
- Benedetti, R., Conte, M., & Altucci, L.
- Venue
- Antioxidants & Redox Signaling
- Publisher
- SAGE Publications
- Published
- 2015-07
- Volume
- 23
- Issue
- 1
- Pages
- 99-126
- ISSN
- 1523-0864 (ISSN-L)
- 1557-7716
- OpenAlex
- W2092000241
- Cited by
- 126
- References
- 39
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.